Theravance Biopharma (TBPH) Cash from Investing Activities Growth (3y) (2016 - 2026)
Theravance Biopharma (TBPH) Cash from Investing Activities Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -39.73% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 296.32% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -53.57% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -246.81% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.84% |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -95.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.46% |
| Mar 31, 2026 | 47.69% |
| Dec 31, 2025 | -75.33% |
| Sep 30, 2025 | -71.93% |
| Jun 30, 2025 | -89.68% |
| Mar 31, 2025 | -1.37% |
| Dec 31, 2024 | 13.16% |
| Sep 30, 2024 | 21.37% |
| Jun 30, 2024 | -27.75% |
| Mar 31, 2024 | -46.89% |
| Dec 31, 2023 | -26.26% |
| Sep 30, 2023 | -26.00% |
| Jun 30, 2023 | 27.29% |
| Mar 31, 2023 | -38.02% |
| Dec 31, 2022 | 40.70% |
| Sep 30, 2022 | 5.88% |
| Jun 30, 2022 | 98.31% |
| Mar 31, 2022 | 34.67% |
| Dec 31, 2021 | -52.25% |
| Sep 30, 2021 | -40.40% |